1826 ET - Cracker Barrel hasn't seen any effects of growing adoption of GLP-1 weight-loss drugs on its sales, Chief Executive Officer Julie Masino says on an analyst call. "We have been actively monitoring GLP-1s for over a year now," she says. "We have not seen any measurable impact at Cracker Barrel to date." She adds that the company offers portion flexibility, substantial protein offerings, and lighter options on its menu. (elias.schisgall@wsj.com)
(END) Dow Jones Newswires
June 09, 2026 18:26 ET (22:26 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.